Granzyme B degrades extracellular matrix and contributes to delayed wound closure in apolipoprotein e knockout mice

Cell Death and Differentiation

Volumn 20, Issue 10, 2013, Pages 1404-1414

  Hiebert, P R ^a   Wu, D ^a   Granville, D J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

extracellular matrix; Granzyme B; inflammation; skin; wound healing

Indexed keywords

APOLIPOPROTEIN E; FIBRONECTIN; GRANZYME B; VITRONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; CHRONIC WOUND; CONTROLLED STUDY; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; GRANULATION TISSUE; KNOCKOUT MOUSE; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; WOUND CLOSURE; WOUND HEALING IMPAIRMENT;

MURINAE; MUS;

ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS E; EXTRACELLULAR MATRIX; GRANZYMES; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; WOUND HEALING;

EID: 84883753169     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.96     Document Type: Article

References (58)

1. Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 2009; 17: 763-771.
2. Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF. Impaired wound healing. Clin Dermatol 2007; 25: 19-25. (Pubitemid 46177472)
3. Boivin WA, Cooper DM, Hiebert PR, Granville DJ. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 2009; 89: 1195-1220.
4. Cullen SP, Martin SJ. Mechanisms of granule-dependent killing. Cell Death Differ 2008; 15: 251-262.
5. Waterhouse NJ, Clarke CJ, Sedelies KA, Teng MW, Trapani JA. Cytotoxic lymphocytes; instigators of dramatic target cell death. Biochem Pharmacol 2004; 68: 1033-1040. (Pubitemid 39094267)
6. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC, Granzyme B. A natural born killer. Immunol Rev 2003; 193: 31-38.
7. Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol Rev 2010; 235: 105-116.
8. Froelich CJ, Pardo J, Simon MM. Granule-associated serine proteases: granzymes might not just be killer proteases. Trends Immunol 2009; 30: 117-123.
9. Granville DJ. Granzymes in disease: bench to bedside. Cell Death Differ 2010; 17: 565-566.
10. Hiebert PR, Granville DJ. Granzyme B in injury, inflammation, and repair. Trends Mol Med 2012; 18: 732-741.
11. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471.
12. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
13. Hui DY, Harmony JA, Innerarity TL, Mahley RW. Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B. J Biol Chem 1980; 255: 11775-11781. (Pubitemid 11132191)
14. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14: 55-61. (Pubitemid 26301547)
15. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986; 136: 3716-3723. (Pubitemid 16122069)
16. Zhang HL, Wu J, Zhu J. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Dev Immunol 2010; 2010: 186813.
17. Hiebert PR, Boivin WA, Abraham T, Pazooki S, Zhao H, Granville DJ. Granzyme B contributes to extracellular matrix remodeling and skin aging in apolipoprotein E knockout mice. Exp Gerontol 2011; 46: 489-499.
18. Feingold KR, Elias PM, Mao-Qiang M, Fartasch M, Zhang SH, Maeda N. Apolipoprotein E deficiency leads to cutaneous foam cell formation in mice. J Invest Dermatol 1995; 104: 246-250.
19. Williams JZ, Barbul A. Nutrition and wound healing. Surg Clin North Am 2003; 83: 571-596. (Pubitemid 36687715)
20. Sgonc R, Gruber J. Age-related aspects of cutaneous wound healing: a mini-review. Gerontology 2013; 59: 159-164.
21. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341: 738-746. (Pubitemid 29407375)
22. Asaga H, Kikuchi S, Yoshizato K. Collagen gel contraction by fibroblasts requires cellular fibronectin but not plasma fibronectin. Exp Cell Res 1991; 193: 167-174. (Pubitemid 121004349)
23. Corbett SA, Schwarzbauer JE. Requirements for alpha(5)beta(1) integrin-mediated retraction of fibronectin-fibrin matrices. J Biol Chem 1999; 274: 20943-20948.
24. Valenick LV, Hsia HC, Schwarzbauer JE. Fibronectin fragmentation promotes alpha4beta1 integrin-mediated contraction of a fibrin-fibronectin provisional matrix. Exp Cell Res 2005; 309: 48-55. (Pubitemid 41191222)
25. Sethi KK, Yannas IV, Mudera V, Eastwood M, McFarland C, Brown RA. Evidence for sequential utilization of fibronectin, vitronectin, and collagen during fibroblast-mediated collagen contraction. Wound Repair Regen 2002; 10: 397-408. (Pubitemid 36025339)
26. Taliana L, Evans MD, Dimitrijevich SD, Steele JG. Vitronectin or fibronectin is required for corneal fibroblast-seeded collagen gel contraction. Invest Ophthalmol Vis Sci 2000; 41: 103-109. (Pubitemid 30036555)
27. Buzza MS, Zamurs L, Sun J, Bird CH, Smith AI, Trapani JA et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem 2005; 280: 23549-23558. (Pubitemid 40884833)
28. Choy JC, Hung VH, Hunter AL, Cheung PK, Motyka B, Goping IS et al. Granzyme B induces smooth muscle cell apoptosis in the absence of perforin: involvement of extracellular matrix degradation. Arterioscler Thromb Vasc Biol 2004; 24: 2245-2250. (Pubitemid 39658024)
29. Hendel A, Granville DJ. Granzyme B cleavage of fibronectin disrupts endothelial cell adhesion, migration and capillary tube formation. Matrix Biol 2012; 2: 14-22.
30. Kaiserman D, Bird CH, Sun J, Matthews A, Ung K, Whisstock JC et al. The major human and mouse granzymes are structurally and functionally divergent. J Cell Biol 2006; 175: 619-630. (Pubitemid 44790615)
31. Boivin WA, Shackleford M, Vanden Hoek A, Zhao H, Hackett TL, Knight DA et al. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-beta1. PLoS One 2012; 7: e33163.
32. Froelich CJ, Zhang X, Turbov J, Hudig D, Winkler U, Hanna WL. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J Immunol 1993; 151: 7161-7171. (Pubitemid 24001090)
33. Chamberlain CM, Ang LS, Boivin WA, Cooper DM, Williams SJ, Zhao H et al. Perforin-independent extracellular granzyme B activity contributes to abdominal aortic aneurysm. Am J Pathol 2010; 176: 1038-1049.
34. Omoto Y, Yamanaka K, Tokime K, Kitano S, Kakeda M, Akeda T et al. Granzyme B is a novel interleukin-18 converting enzyme. J Dermatol Sci 2010; 59: 129-135.
35. Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, Luthi AU et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell 2011; 44: 265-278.
36. Choy JC. Granzymes and perforin in solid organ transplant rejection. Cell Death Differ 2010; 17: 567-576.
37. Thomas HE, Trapani JA, Kay TW. The role of perforin and granzymes in diabetes. Cell Death Differ 2010; 17: 577-585.
38. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010; 17: 616-623.
39. Darrah E, Rosen A. Granzyme B cleavage of autoantigens in autoimmunity. Cell Death Differ 2010; 17: 624-632.
40. Hendel A, Hiebert PR, Boivin WA, Williams SJ, Granville DJ. Granzymes in age-related cardiovascular and pulmonary diseases. Cell Death Differ 2010; 17: 596-606.
41. Kim WJ, Kim H, Suk K, Lee WH. Macrophages express granzyme B in the lesion areas of atherosclerosis and rheumatoid arthritis. Immunol Lett 2007; 111: 57-65. (Pubitemid 47017480)
42. Choy JC, McDonald PC, Suarez AC, Hung VH, Wilson JE, McManus BM et al. Granzyme B in atherosclerosis and transplant vascular disease: association with cell death and atherosclerotic disease severity. Mod Pathol 2003; 16: 460-470. (Pubitemid 36618467)
43. Jarvelainen H, Puolakkainen P, Pakkanen S, Brown EL, Hook M, Iozzo RV et al. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen 2006; 14: 443-452. (Pubitemid 44266601)
44. Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol 2009; 9: 57-62.
45. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005; 23(Suppl 1): S10-S25.
46. Chandra RK. Nutrition and the immune system: an introduction. Am J Clin Nutr 1997; 66: 460S-463S. (Pubitemid 27360349)
47. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen 1999; 7: 433-441 (Pubitemid 30027565)
48. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997; 136: 729-743. (Pubitemid 27083772)
49. Weber IT, Harrison RW, Iozzo RV. Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 1996; 271: 31767-31770. (Pubitemid 26422189)
50. Ang LS, Boivin WA, Williams SJ, Zhao H, Abraham T, Carmine-Simmen K et al. Serpina3n attenuates granzyme B-mediated decorin cleavage and rupture in a murine model of aortic aneurysm. Cell Death Dis 2011; 2: e209.
51. Grinnell F, Ho CH, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J Invest Dermatol 1992; 98: 410-416.
52. Wysocki AB, Grinnell F. Fibronectin profiles in normal and chronic wound fluid. Lab Invest 1990; 63: 825-831.
53. Stanley CM, Wang Y, Pal S, Klebe RJ, Harkless LB, Xu X et al. Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. J Periodontol 2008; 79: 861-875.
54. Ongenae KC, Phillips TJ, Park HY. Level of fibronectin mRNA is markedly increased in human chronic wounds. Dermatol Surg 2000; 26: 447-451. (Pubitemid 30305324)
55. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687. (Pubitemid 35283958)
56. Ugarova TP, Ljubimov AV, Deng L, Plow EF. Proteolysis regulates exposure of the IIICS-1 adhesive sequence in plasma fibronectin. Biochemistry 1996; 35: 10913-10921. (Pubitemid 26279674)
57. Poe M, Blake JT, Boulton DA, Gammon M, Sigal NH, Wu JK et al. Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J Biol Chem 1991; 266: 98-103. (Pubitemid 21906095)
58. Murphy ME, Moult J, Bleackley RC, Gershenfeld H, Weissman IL, James MN. Comparative molecular model building of two serine proteinases from cytotoxic T lymphocytes. Proteins 1988; 4: 190-204. (Pubitemid 19021546)